Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies

New England Journal of Medicine published OLUMIANT 36-week alopecia areata data today INDIANAPOLIS , March 26, 2022 /PRNewswire/ -- Adults with severe alopecia areata (AA) who took OLUMIANT ® (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who